• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >V-CLIP: Integrating Plasma Vascular Endothelial Growth Factor Into a New Scoring System to Stratify Patients With Advanced Hepatocellular Carcinoma for Clinical Trials
【24h】

V-CLIP: Integrating Plasma Vascular Endothelial Growth Factor Into a New Scoring System to Stratify Patients With Advanced Hepatocellular Carcinoma for Clinical Trials

机译：V-CLIP：将血浆血管内皮生长因子整合到一个新的计分系统中，以对晚期肝细胞癌患者进行临床试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the United States, the incidence of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, has been steadily rising over the last 3 decades.1 A recent study indicated that the incidence rate of HCC in the United States tripled from 1975 to 2005.The management of patients with advanced, unresectable HCC presents several challenges, including the need for prognostic staging systems to predict prognosis and stratify patients on clinical trial. Therefore, increasingly specific parameters have been used to evaluate survival and prognosis of HCC patients, starting with the presence of cirrhosis, because the prognosis of HCC depends not only on tumor size but also on underlying liver function. A limitation of the Child-Pugh score, which reflects the degree of hepatic reserve in patients with cirrhosis, is the lack of any parameter that directly pertains to the tumor itself.3 Therefore, the concept of adding more parameters to assess the tumor status was established, and subsequently several clinical staging systems for HCC have been proposed, including the Cancer of the Liver Italian Program (CLIP), and the Barcelona Clinic Liver Cancer (BCLC) staging system.
机译：在美国，过去三十年来，最常见的原发性肝癌形式肝细胞癌（HCC）的发病率一直在稳步上升。1最近的一项研究表明，美国的HCC发病率是1975年至2005年。对无法切除的晚期HCC患者的管理提出了许多挑战，包括需要使用预后分期系统来预测预后并在临床试验中对患者进行分层。因此，从肝硬化的出现开始，越来越多的特定参数已用于评估HCC患者的生存和预后，因为HCC的预后不仅取决于肿瘤的大小，还取决于潜在的肝功能。反映肝硬化患者肝储备程度的Child-Pugh评分的局限性在于缺少与肿瘤本身直接相关的任何参数。3因此，增加更多参数以评估肿瘤状态的概念是建立了肝癌的临床分期系统，随后提出了几种临床分期系统，包括意大利肝癌计划（CLIP）和巴塞罗那临床肝癌（BCLC）分期系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号